OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Cancer Research and Clinical Oncology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients	168
Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study	100
Heterodimerization of cholecystokinin 1 and cholecystokinin 2 receptors in gallbladder cancer: a new mechanism for carcinogenesis	84
A case of rare metachronous four primary carcinoma	74
A predictive model for patients with local-regionally advanced oropharyngeal squamous cell carcinoma treated after cervical lymph node dissection	71
Radiomics-guided prognostic assessment of early-stage hepatocellular carcinoma recurrence post-radical resection	68
Clinical characteristics and long-term outcomes of rhabdomyosarcoma in Korean children, adolescents and young adults: a single-center experience	63
Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case rep	59
Performance of endobronchial ultrasound transbronchial needle aspiration as the first nodal staging procedure for the determination of programmed death ligand-1 expression in non-small cell lung cance	58
Combination of multiple nucleic acid aptamers for precision detection of tumors based on optical methods	57
Extracellular urinary microRNAs as non-invasive biomarkers of endometrial and ovarian cancer	53
Exportin XPO7 acts as an oncogenic factor in prostate cancer via upregulation of TCF3	52
Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy	52
Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma	52
Clinical characteristics of sarcoma patients: a population-based data analysis from a German clinical cancer registry	50
Attitudes toward a COVID-19 vaccine and vaccination status in cancer patients: correspondence	47
Comprehensive bioinformatics analysis of a RBM family-based prognostic signature with experiment validation in hepatocellular carcinoma	47
Can whole-body MRI replace CT in management of metastatic testicular cancer? A prospective, non-inferiority study	46
GSTM1 and GSTT1 polymorphisms associated with pain in a chemotherapy-induced peripheral neuropathy cohort	43
Expression and clinical prognostic value of CYB561 in breast cancer	43
Introducing a standardized assessment of patients’ interest in and usage of CAM in routine cancer care: chances and risks from patients’ and physicians’ point of view	42
Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma	42
MET overexpression in EGFR L858R mutant treatment-naïve advanced lung adenocarcinoma correlated with poor prognosis: a real-world retrospective study	39
Single-center experience in the diagnosis and treatment of lymphoepithelioma-like hepatic carcinoma	39
Comment on “Predicting metastasis at initial diagnosis and radiotherapy effectiveness in patients with metastatic osteosarcoma”	38

Claudins as biomarkers of differential diagnosis and prognosis of tumors	38
High USP4 mRNA is associated with an HPV-positive status in head and neck squamous cell carcinoma patients	38
Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study	37
Relevance of tumor boards for the inclusion of patients in oncological clinical trials	34
Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ	33
The role of the Nrf2/GSH antioxidant system in cisplatin resistance in malignant rhabdoid tumours	33
Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas	32
Systematic analysis of mistletoe prescriptions in clinical studies	32